JP2020510422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510422A5 JP2020510422A5 JP2019546327A JP2019546327A JP2020510422A5 JP 2020510422 A5 JP2020510422 A5 JP 2020510422A5 JP 2019546327 A JP2019546327 A JP 2019546327A JP 2019546327 A JP2019546327 A JP 2019546327A JP 2020510422 A5 JP2020510422 A5 JP 2020510422A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- cancer
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022118823A JP2022141910A (ja) | 2017-02-28 | 2022-07-26 | 抗ｔｉｇｉｔ抗体 |
| JP2024026609A JP2024057038A (ja) | 2017-02-28 | 2024-02-26 | 抗ｔｉｇｉｔ抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464529P | 2017-02-28 | 2017-02-28 | |
| US62/464,529 | 2017-02-28 | ||
| US201862616779P | 2018-01-12 | 2018-01-12 | |
| US62/616,779 | 2018-01-12 | ||
| PCT/US2018/020239 WO2018160704A1 (en) | 2017-02-28 | 2018-02-28 | Anti-tigit antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022118823A Division JP2022141910A (ja) | 2017-02-28 | 2022-07-26 | 抗ｔｉｇｉｔ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510422A JP2020510422A (ja) | 2020-04-09 |
| JP2020510422A5 true JP2020510422A5 (https=) | 2021-04-08 |
Family
ID=63370305
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546327A Withdrawn JP2020510422A (ja) | 2017-02-28 | 2018-02-28 | 抗ｔｉｇｉｔ抗体 |
| JP2022118823A Pending JP2022141910A (ja) | 2017-02-28 | 2022-07-26 | 抗ｔｉｇｉｔ抗体 |
| JP2024026609A Pending JP2024057038A (ja) | 2017-02-28 | 2024-02-26 | 抗ｔｉｇｉｔ抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022118823A Pending JP2022141910A (ja) | 2017-02-28 | 2022-07-26 | 抗ｔｉｇｉｔ抗体 |
| JP2024026609A Pending JP2024057038A (ja) | 2017-02-28 | 2024-02-26 | 抗ｔｉｇｉｔ抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200040082A1 (https=) |
| EP (1) | EP3589313A4 (https=) |
| JP (3) | JP2020510422A (https=) |
| KR (1) | KR20190123749A (https=) |
| CN (1) | CN111050788A (https=) |
| AU (2) | AU2018227489B2 (https=) |
| BR (1) | BR112019017550A2 (https=) |
| CA (1) | CA3053486A1 (https=) |
| IL (1) | IL268517A (https=) |
| MA (1) | MA47694A (https=) |
| MX (2) | MX2019010206A (https=) |
| SG (2) | SG11201907278VA (https=) |
| WO (1) | WO2018160704A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| JP7178906B2 (ja) | 2016-05-19 | 2022-11-28 | ザ ジェネラル ホスピタル コーポレイション | ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ |
| MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| AU2019337974A1 (en) | 2018-09-11 | 2021-04-08 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US20200318200A1 (en) | 2019-04-02 | 2020-10-08 | The Brigham And Women's Hospital, Inc. | Methods for Identifying Progression of a Primary Melanoma |
| KR102332847B1 (ko) * | 2019-06-13 | 2021-12-01 | 주식회사 녹십자 | Tigit에 대한 항체 및 이의 용도 |
| EP3986936A4 (en) * | 2019-06-21 | 2023-03-15 | Single Cell Technology, Inc. | ANTI-TIGIT ANTIBODIES |
| CN114728171A (zh) * | 2019-11-05 | 2022-07-08 | 默克专利有限公司 | 抗tigit抗体及其应用 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CN112409450B (zh) * | 2020-03-29 | 2023-01-24 | 郑州大学 | TIGIT-IgV的亲和剂及其应用 |
| CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| WO2021258337A1 (en) * | 2020-06-24 | 2021-12-30 | Huahui Health Ltd. | Human monoclonal antibodies against tigit for immune related diseases |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| EP4192883A4 (en) * | 2020-08-05 | 2024-12-04 | Crystal Bioscience Inc. | Anti-tigit antibody and methods of use thereof |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4294948A1 (en) | 2021-02-17 | 2023-12-27 | iTeos Belgium SA | Compounds, compositions and methods of treatment thereof |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025255297A1 (en) * | 2024-06-05 | 2025-12-11 | Agilent Technologies, Inc. | Anti-human tigit antibodies for in vitro diagnostics |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016000853A2 (pt) * | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| US20150132744A1 (en) * | 2013-11-13 | 2015-05-14 | Oregon Health And Science University | Methods of detecting cells latently infected with hiv |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN108290936B (zh) * | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| PE20181046A1 (es) * | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
-
2018
- 2018-02-28 EP EP18760515.9A patent/EP3589313A4/en not_active Withdrawn
- 2018-02-28 JP JP2019546327A patent/JP2020510422A/ja not_active Withdrawn
- 2018-02-28 KR KR1020197027438A patent/KR20190123749A/ko active Pending
- 2018-02-28 MX MX2019010206A patent/MX2019010206A/es unknown
- 2018-02-28 SG SG11201907278VA patent/SG11201907278VA/en unknown
- 2018-02-28 AU AU2018227489A patent/AU2018227489B2/en not_active Ceased
- 2018-02-28 WO PCT/US2018/020239 patent/WO2018160704A1/en not_active Ceased
- 2018-02-28 CN CN201880027323.6A patent/CN111050788A/zh active Pending
- 2018-02-28 SG SG10202103227YA patent/SG10202103227YA/en unknown
- 2018-02-28 MA MA047694A patent/MA47694A/fr unknown
- 2018-02-28 BR BR112019017550-4A patent/BR112019017550A2/pt not_active Application Discontinuation
- 2018-02-28 CA CA3053486A patent/CA3053486A1/en active Pending
-
2019
- 2019-08-05 IL IL268517A patent/IL268517A/en unknown
- 2019-08-15 US US16/541,575 patent/US20200040082A1/en not_active Abandoned
- 2019-08-27 MX MX2023006212A patent/MX2023006212A/es unknown
-
2020
- 2020-10-28 US US17/082,586 patent/US20210269527A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/853,134 patent/US20230134375A1/en not_active Abandoned
- 2022-07-26 JP JP2022118823A patent/JP2022141910A/ja active Pending
-
2024
- 2024-01-10 AU AU2024200157A patent/AU2024200157A1/en not_active Abandoned
- 2024-02-26 JP JP2024026609A patent/JP2024057038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510422A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2020501531A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| JP2019528779A5 (https=) | ||
| IL273424B1 (en) | Novel bispecific cd3/cd19 polypeptide complexes | |
| JP2018523493A5 (https=) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2018507188A5 (https=) | ||
| JP2018503365A5 (https=) | ||
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2013056885A5 (https=) | ||
| JP2018520657A5 (https=) | ||
| RU2017105915A (ru) | Антитела против pd-1 | |
| JP2022533538A5 (https=) | ||
| JP2023516004A5 (https=) | ||
| JP2026041845A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP2022553129A5 (https=) | ||
| JP2020515277A5 (https=) |